SCI时时刷

search
+
[Viewpoint] COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year
ACTIV-4, REMAP-CAP, and ATTACC multiplatform trials also studied therapeutic dose anticoagulation in patients with COVID-1...
[Editorial] The evolving promise and potential of gene therapy
In the first half of 2021, we have had mixed news from the field of gene therapy. March saw a halt in bluebird bio's gene ...
[Comment] CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia
After 5 years of follow-up, the improved overall survival with CPX-351 versus 7+3 was maintained, which supports the previ...
[Comment] Optical or optimal conclusion: pharmacokinetic-guided dosing in haemophilia
Among individuals with haemophilia, the inherited X-linked disorder caused by deficient factor VIII or factor IX and...
[Comment] Iron preparations for iron deficiency anaemia in pregnancy: which treatment is best?
Iron deficiency anaemia is a common clinical problem in pregnant women worldwide. It affects around 15–20% of women ...
[News] Newborn screening for sickle cell disease in Africa
On April 21, 2021, newborn screening for sickle cell disease was launched at Arthur Davison Children's Hospital in N...
[Correspondence] Sustained prothrombotic changes in convalescent patients with COVID-19
We read with great interest the Viewpoint by Leentjens and colleagues1Leentjens J van Haaps TF Wessels PF Schutgens REG Mi...
[In Focus] Trials and tribulations: including women in cancer clinical research
Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New ZealandDepartment of Haematol...
[Articles] Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial
Background Dosing of replacement therapy with factor VIII concentrate in patients with haemophilia A...
[Articles] CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
Background Daunorubicin and cytarabine are used as standard induction chemotherapy for patients with...
[Review] Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia
1.Bhakta N Liu Q Ness KK et al.The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lif...
[Clinical Picture] Acute lymphoblastic leukaemia presenting as euglycaemic ketoacidosis in a patient with type 1 diabetes
A 21-year-old man presented to the Lausanne University Hospital (CHUV) in August, 2020, with reddened skin lesions o...
[Articles] Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis
1.Systemic iron homeostasis.Physiol Rev. 93: 1721-17412.Barroso F Allard S Kahan BC et al.Prevalence of maternal anaemia a...
[Comment] Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
Multiple myeloma is a malignancy of plasma cells, which is highly associated with immune suppression. Consistent with this...
[In Focus] Matthew Fowler: driving advanced nursing practice in haematology
When Matthew Fowler (consultant nurse for Oncology and Haematology, Heartlands Hospital, Birmingham, UK) first start...
[In Focus] From working in the corporate world to nursing to advocacy
Growing up, I knew exactly what I wanted to do when I finished high school. I had always pictured myself working in ...
[In Focus] Global collaboration led by the EBMT Nurses Group
The success of a haematopoietic stem-cell transplantation (HSCT) programme relies heavily on appropriately trained a...
[Editorial] Bleeding disorders: adapting to change
April 17 marked World Hemophilia Day—a day that brings the global bleeding disorders community together. The theme this ye...
[Comment] A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma
With 5 years of follow-up, A+AVD showed robust and durable improvement in progression-free survival versus ABVD, regardles...
[Comment] Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy
The treatment of multiple myeloma has evolved from being time-limited to a continuous strategy, made possible with t...
[Comment] Anti-CD25 antibody–drug conjugates: improving the delivery of death to lymphoma cells?
In The Lancet Haematology, Mehdi Hamadani and colleagues 1 Hamadani M ...
[Corrections] Correction to Lancet Haematol 2021; 8: e205–15
The DRSS is a novel risk stratification tool including disease features related to histology, genetic profile, and treatme...
[Articles] PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
Background The German Hodgkin Study Group's HD18 trial established the safety and efficacy of PET-gu...
[Corrections] Correction to Lancet Haematol 2021; 8: e185–93
We use cookies to help provide and enhance our service and tailor content and ads. To update your cookie settings, please...
[Articles] Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
Background Lenalidomide maintenance improves progression-free survival for patients with multiple myeloma,...
[Articles] Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
Background Despite advances in the treatment of Hodgkin lymphoma with the introduction of PET-adapted ...
[Review] CAR T-cell therapy for multiple myeloma: state of the art and prospects
1.Gandhi UH Cornell RF Lakshman A et al.Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal ...
[Articles] Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
Intrahepatic cholestasis of pregnancy is a liver disease that slows, or even stops, the normal flow of bile to the gallbla...
[Viewpoint] Eliminating race-based reference ranges in haematology: a call to action
1.The evolution of the reference value concept.Clin Chem Lab Med. 42: 692-6972.Cheng CK Chan J Cembrowski GS van Assendelf...
format_indent_increase